Medical Radiology and Radiation Safety. 2023. Vol. 68. № 3

DOI: 10.33266/1024-6177-2023-68-3-57-65

A.S. Krylov1, B.Ya. Narkevich1, 2, A.D. Ryzhkov1, 3, V.V. Krylov4, T.M. Geliashvili1, A.I. Pronin1

The Efficacy of Radionuclide Therapy for Bone Metastasis

1 N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia 

2Association of Medical Physicists of Russia, Moscow, Russia 

3Russian Medical Academy of Continuous Professional Education, Moscow, Russia

4A.F. Tsyb Medical Radiology Research Center, Obninsk, Russia 

Contact persons: Boris Yaroslavovich Narkevich, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.  



Purpose: Development of a methodology for evaluating the effectiveness of radionuclide therapy for bone metastases based on dosimetric and clinical and laboratory criteria. 

Material and methods: A comparative analysis of the functionality of various criteria for assessing the long-term and short-term effectiveness of radionuclide therapy of bone metastases was carried out. Focal absorbed doses of internal exposure are considered as one of the criteria, for the determination of which a simplified method for their calculation is proposed based on quantitative data from SPECT/CT scanning of an X-ray phantom and a real patient who has been injected with a β-γ-emitting therapeutic radiopharmaceutical. 

Results: On a clinical example of radionuclide therapy with 177Lu-PSMA-617 in a patient with stage 4 prostate cancer, dose estimates of internal irradiation of foci with β-particles were obtained. Calculations were made for bone metastases of 7 localizations in dynamics for each of the 5 fractions of the course of radionuclide therapy. It is shown that the total focal doses for 5 fractions of internal exposure vary from 70.6 to 116.8 Gy for different foci, which corresponds to the literature data obtained by more accurate methods of dosimetry of internal exposure. The obtained dosimetric data were compared with efficacy estimates based on metabolic, hematological, hormonal and biochemical parameters, as well as on the tumor marker PSA. 

Conclusion: The main criterion for assessing the antitumor efficacy of radionuclide therapy is the metabolic activity of bone foci, while data on the accumulated focal doses of internal β-irradiation are of an auxiliary nature. Hematological indicators should be the criteria for assessing radiotoxicity and used to adjust the course of radionuclide therapy.

Keywords: radionuclide therapy, β-γ-emitting radiopharmaceuticals, bone metastases, internal irradiation, therapy effectiveness, evaluation criteria, dosimetric parameters, clinical and laboratory parameters

For citation: Krylov AS, Narkevich BYa, Ryzhkov AD, Krylov VV, Geliashvili TM, Pronin AI. The Efficacy of Radionuclide Therapy for Bone Metastasis. Medical Radiology and Radiation Safety. 2023;68(3):57–65. (In Russian). DOI: 10.33266/1024-6177-2023-68-3-57-65



  1. ICRU Report 96. Dosimetry-Guided Radiopharmaceutical Therapy. Journal of ICRU. 2021; 21(1).
  2.  Росcийские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под рук. И.В. Поддубной, В.Г. Савченко М.: ММА МедиаМедика, 2014. [Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Poddubnaya IV, Savchenko VG. M.: MMA MediaMedica, 2014. (In Russian)].
  3. Гележе П. В., Морозов С. П., Мандельблат Ю. Э., Либсон Е. И. Что нового в критериях оценки онкологических заболеваний в лучевой диагностике: RECIST vs. PERCIST. Лучевая диагностика и терапия. 2014. № 2(5). С. 28–36. [Gelezhe PV, Morozov SP, Mandelblat YuE, Libson EI. Whatʼs News in Cancer Evaluation Criteria in Medical Imaging: RECIST vs. PERCIST. Radiation Diagnostics and Therapy. 2014; (2(5)):28-36. (In Russian)].
  4. Bentzen SM, Constine LS, Deasy JO, et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010; 76(3): 3–9.
  5. Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nature Reviews: Drug Discovery. 2020; 19: 589-608.
  6. Наркевич Б.Я., Крылов А.С., Рыжков А.Д. Упрощенный способ расчета доз внутреннего облучения костных метастазов при радионуклидной терапии. Медицинская физика. 2023. № 1(97). С. 43-56. [Narkevich BYa, Krylov AS, Ryzhkov AD. A simplified method for calculating internal doses of bone metastases during radionuclide therapy. Medical Physics. 2023;(1(97)):43-56. (In Russian)].



 PDF (RUS) Full-text article (in Russian)


Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 20.01.2022. Accepted for publication: 25.02.2023.